Elpipodect
Sponsors
Merck Sharp & Dohme LLC
Conditions
Alzheimer's DiseaseBipolar I DisorderHepatic ImpairmentSchizophreniaSchizophrenia, Acute Episode
Phase 1
Elpipodect (MK-8189) Multiple Dose Study in Healthy Volunteers and Schizophrenia Participants (MK-8189-003)
CompletedNCT02181803
Start: 2014-08-05End: 2015-04-23Updated: 2026-04-29
Safety, Tolerability, and Pharmacokinetics Study of Elpipodect (MK-8189) in Participants With Schizophrenia and Healthy Participants (MK-8189-011)
CompletedNCT04506905
Start: 2020-08-28End: 2022-03-22Updated: 2026-04-29
A Study to Investigate the Influence of Hepatic Impairment on Elpipodect (MK-8189) Treatment (MK-8189-012)
CompletedNCT04676425
Start: 2021-03-17End: 2022-01-25Updated: 2026-04-29
Elpipodect (MK-8189) Safety and Tolerability in Participants With Alzheimer's Disease With or Without Symptoms of Agitation-Aggression and/or Psychosis (MK-8189-017)
CompletedNCT05227118
Start: 2022-07-01End: 2023-01-10Updated: 2026-04-29
A Study of Elpipodect (MK-8189) in Participants With Schizophrenia (MK-8189-014)
CompletedNCT05406440
Start: 2022-07-12End: 2023-02-24Updated: 2026-04-29
A Study To Evaluate The Effect Of A Supratherapeutic Dose Of Elpipodect (MK-8189) On The QTc Interval In Participants With Schizophrenia (MK-8189-019)
CompletedNCT05893862
Start: 2023-06-26End: 2024-02-22Updated: 2026-04-29
A Study of Elpipodect (MK-8189) in Participants With Bipolar I Disorder (MK-8189-020)
CompletedNCT06273774
Start: 2024-04-08End: 2024-08-21Updated: 2026-04-29
Phase 2
An Active-Controlled Early Phase Study of Elpipodect (MK-8189) in Adults With Schizophrenia (MK-8189-005)
CompletedNCT03055338
Start: 2017-03-08End: 2018-01-09Updated: 2026-04-29
Efficacy and Safety of Elpipodect (MK-8189) in Participants With an Acute Episode of Schizophrenia (MK-8189-008)
CompletedNCT04624243
Start: 2020-12-15End: 2024-06-21Updated: 2026-04-29